

## ***Rheumatology Award 1993***

*Roche has an extensive commitment to research at its United Kingdom Research Centre. One of the major programmes is directed to the search for novel approaches to the treatment of arthritis. In view of its interest in this field Roche established in 1989 an award to mark outstanding achievement rheumatology research of a clinical nature. The award is for £10,000 for work undertaken in the United Kingdom by a researcher under 40 years of age.*

*The award is in two equal parts; a personal prize for the researcher, and a bursary for his or her unit. A panel of experts representative of rheumatology research will be responsible for the choice of award winner.*

*Full details of the Roche Rheumatology Award may be obtained from:-*



*Mr Nigel Davies  
Roche Products Limited  
PO Box 8  
Welwyn Garden City  
Herts AL7 3AY*

*The closing date for applications is 20 July 1993*

# Clinical and Experimental

# RHEUMATOLOGY

An independent, international journal conveying the latest in the field of rheumatology


**Editors:** Stefano Bombardieri, MD (*Chief*) (Italy), Barbara M. Ansell, MD (*Pediatric Rheumatology section*) (UK),  
Graham R.V. Hughes, MD (UK), Haralampos M. Moutsopoulos, MD (*Greece*), Paul E. Phillips, MD (USA)

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY provides a international forum for both clinicians and scientists wishing to keep up with the latest developments in the field of rheumatology. In addition to *Original Articles*, *Rapid Papers*, and *Case Reports*, every issue contains an *Editorial* and a *Review* designed to update readers on the hottest topics in this complex and rapidly growing field.

We were also the first in our field to introduce a regular section on **Pediatric Rheumatology**.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY is not the official organ of any professional society and is proud of its editorial independence. Our international editorial board and outside referees provide a fair and careful screening of all articles submitted for publication.

Subscribe now and keep abreast of what's happening around the world in rheumatology! We are offering very special rates for professionals in training, and ACR and EULAR members.



✂-----

## CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

via S. Maria 31, 56126 Pisa, Italy      tel: (50) 40124 Fax: (50) 553.444

- Please send me a complementary copy of the journal.
- Please enter my subscription for the calendar year 1993 (6 issues plus supplements).

	<u>Italy</u>	<u>Europe</u>	<u>Other</u>
<input type="checkbox"/> Individual	Lit. 85.000	\$115	\$115 / \$145*
<input type="checkbox"/> Institutional	Lit. 120.000	\$135	\$135 / \$165*
<input type="checkbox"/> In-training**	Lit. 45.000	\$45	\$45
<input type="checkbox"/> ACR and EULAR members	<b>\$85.00</b>		

- Check enclosed (payable to *Clinical & Experimental Rheumatology*)
- Please charge to my credit card account (*circle one*):  
AMERICAN EXPRESS / DINERS / VISA / MASTERCARD / EUROCARD

Credit card no. \_\_\_\_\_ Expiration date \_\_\_\_\_

First name \_\_\_\_\_ Last name \_\_\_\_\_

Signature \_\_\_\_\_

Professional address: \_\_\_\_\_

Home address: \_\_\_\_\_

Advance payment is required. Payments from abroad must be by international cheque or credit card.  
Rates include supplements and postage. Issues are sent overseas by surface mail (\*The higher rate reflects the surcharge for air mail delivery).  
Individual subscriptions must be in the name of and paid for by the individual. \*\*Students, trainees and fellows must include a letter from their supervisor.



# Healthy future?



## London after Tomlinson Re-organising big city medicine



Health services in many big cities, in Britain and elsewhere, are no longer appropriate to serve populations that have moved out to the suburbs. Commissioned by the government to provide some answers to London's health care problems, the Tomlinson report raises as many questions:

- \* What are the implications of its proposals for the future of health care in London and other big cities?
- \* How are the substantial improvements in primary and community health care to be brought about?
- \* What support is needed for teaching and research?

In *London after the Tomlinson* experts look at the issues raised by the report and suggest solutions. Whatever the decisions made for London, it is clear that the problems are not unique to London but are shared by many other large cities both in the United Kingdom and in other developed countries.

ISBN 0 7279 0783 2 96 pages 1993

Price: UK £8.95; Overseas £11.00 (BMA members: UK £8.45, Overseas: £10.50)



### The Health Debate Live: 45 Interviews for leading for health

The original transcripts of interviews held for the BMA document *Leading for health: A BMA Agenda for Health*, published in 1992.

"...the BMA is to be congratulated on producing a compilation ... which provides a challenging, sometimes familiar, glimpse into the diversity of opinion to be found in the health service today"

*Health Services Management*

ISBN 0 7279 0740 9 192 pages 1992

Price UK £10.95; Overseas £13.00  
(BMA members £9.95 or £12.00)

### The Health of a Nation: the BMJ View

Edited by Richard Smith

A collection of 28 essays commissioned by the BMJ in response to the Government's consultative document 'The Health of the Nation' which was published in 1991.

"It provides the essential referenced background material for making a start in virtually any important clinical or social field of primary care."

*Family Practice*

ISBN 0 7279 0314 4 240 pages 1991

Price UK £9.95; Overseas £12.00  
(BMA members £8.95 or £11.00)

### The Future of Health Care

Experts write about the main topics on the BMA's "agenda for health" - such as rationing of care and funding of services - and suggest action for the future.

"For anyone interested in the future of the NHS, this book can be recommended as a useful starting point."

*Journal of Epidemiology and Community Health*

ISBN 0 7279 0742 5 104 pages 1992

Price UK £8.95; Overseas £10.00  
(BMA members £8.45 or £9.50)

**BMJ**  
PUBLISHING GROUP

## ORDER FORM British Medical Journal, PO Box 295, London WC1H 9TE

Please send me the following books:

Qty	Title	Amount
Prices include postage by air abroad <input type="checkbox"/> Please send me a book catalogue		Total £

Name \_\_\_\_\_ Membership No \_\_\_\_\_

Address \_\_\_\_\_

Postcode \_\_\_\_\_

Cheque enclosed (made payable to British Medical Journal) £ \_\_\_\_\_

Debit my AMERICAN EXPRESS / VISA / MASTERCARD Card No \_\_\_\_\_

Signature \_\_\_\_\_ Expiry date \_\_\_\_\_


BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only).

# Is early joint damage acceptable in today's RA patient?

Majority of patients with Rheumatoid Arthritis (RA) suffer erosive joint damage within 2 years of symptom onset offering a relatively narrow window of opportunity when disease modifying treatment can achieve most.<sup>1</sup>

Today, our potential to suppress early joint damage in RA is highlighted by the results of a recent trial.<sup>2</sup> In this double-blind, randomised study in patients of median disease duration less than 9 months a significant slowing of joint damage was evident with Salazopyrin EN-tabs compared with hydroxychloroquine at 24 and 48 weeks.<sup>2</sup> Furthermore, the difference was still significant at 3-year follow-up.<sup>3</sup> In the words of the authors, "the first blow is half the battle".<sup>3</sup>

Radiographic progression in patients treated with Salazopyrin EN-tabs or hydroxychloroquine.<sup>2,3</sup>



When NSAIDs alone fail to preserve function and mobility

## Salazopyrin<sup>®</sup> EN-tabs

enteric coated sulphasalazine

Today's choice to preserve tomorrow's lifestyle

1. Jansen J, van der Helm-van Mil AHM, van der Heijde DMJM, et al. Radiographic progression in patients treated with Salazopyrin EN-tabs or hydroxychloroquine. *Ann Rheum Dis* 2005; 64: 1033-1038. 2. Jansen J, van der Helm-van Mil AHM, van der Heijde DMJM, et al. Radiographic progression in patients treated with Salazopyrin EN-tabs or hydroxychloroquine. *Ann Rheum Dis* 2005; 64: 1033-1038. 3. Jansen J, van der Helm-van Mil AHM, van der Heijde DMJM, et al. Radiographic progression in patients treated with Salazopyrin EN-tabs or hydroxychloroquine. *Ann Rheum Dis* 2005; 64: 1033-1038.